Recruiting
Phase 1

FAraG PET Imaging

Sponsor:

CellSight Technologies, Inc.

Code:

NCT03142204

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

[18F]F-AraG

Study Details

Brief summary:

This is a Phase 1 study is to visualize biodistribution of a PET tracer called \[18F\]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.

Conditions

Cancer

Study ID

NCT03142204

Start date

May 1, 2017

Status verified date

Dec, 2022

Completion date

May, 2024

Anticipated

Primary completion date

May, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Cancer patients with identified tumor mass
  • Cancer patients expected to undergo immunotherapy and/or radiation therapy

Exclusion Criteria:

  • Under the age of 18
  • Pregnant women
  • Women who are breastfeeding
  • Individuals with known or suspected substance abuse
  • Individuals unable or unwilling to comply with the study procedures

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Interventions

[18F]F-AraG

Single dose IV injection of \[18F\]F-AraG for each imaging day.

Primary outcome measure

  • Visualize biodistribution of the PET tracer [18F]F-AraG pre-immunotherapy [ Time Frame: Up to 6 weeks before immunotherapy is administered ]
  • Visualize biodistribution of the PET tracer [18F]F-AraG post start of immunotherapy [ Time Frame: Up to 12 weeks after start of immunotherapy ]

Central Contacts and Locations

Central contacts

Robert R Flavell, M.D., Ph.D.

917-509-8679robert.flavell@ucsf.edu

Henry VanBrocklin, Ph.D.

415-353-4569henry.vanbrocklin@radiology.ucsf.edu

Locations

UCSF Imaging Center at China Basin

Recruiting

San Francisco, California, United States, 94107

Contacts

Maya Aslam

415-514-8987maya.aslam@ucsf.edu

Katherine Wu

415-353-9437katherine.wu@ucsf.edu

More Information

Sponsor

CellSight Technologies, Inc.

Last update posted

Dec 5, 2022

Last verified

Dec, 2022

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by CellSight Technologies, Inc. on 2022-12-05.